{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:12:46Z","timestamp":1781619166703,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["Sanofi"],"award-info":[{"award-number":["Sanofi"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Pompe disease and Mucopolysaccharidoses Type I (MPS-I) are lysosomal disorders caused by a deficiency of \u03b1-glucosidase and alpha-L-iduronidase, respectively. The mainstay of treatment is enzyme replacement therapy (ERT), a life-long treatment that requires regular I.V. infusions. Hospital-based therapy can, however, negatively impact quality of life over time. The purpose of the HomERT study (Home infusions of ERT) was to evaluate the safety, treatment compliance, and treatment satisfaction related to home therapy of Pompe disease patients with Myozyme\n                      <jats:sup>\u00ae<\/jats:sup>\n                      (alglucosidase alfa) and MPS-I patients with Aldurazyme\n                      <jats:sup>\u00ae<\/jats:sup>\n                      (laronidase). The final results are presented in this paper.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The HomERT study was a multicenter, non-interventional, minimum 12-month prospective observational, double-cohort study that analyzed 56 patients from 14 sites in Italy from October 2021 to February 2024: cohort A (Pompe disease \u2212\u200947 patients) and cohort B (MPS-I \u2212\u20099 patients: 6 Hurler\/Scheie, 3 Scheie). During the observation period, the mean (SD) number of missed infusions was 5.8 (3.92) in cohort A and 3.0 (3.52) in cohort B, corresponding to a mean (SD) of missed infusions of 19.8 (32.7)% and 4.1 (4.2)%, respectively, versus the number of planned infusions. Only 2 patients in cohort A returned to the hospital setting due to \u201cadverse event\u201d and \u201cother\u201d reasons. A total of 13 Adverse Drug Reactions (ADR) were reported during the home-care setting before and after enrollment. The average number of ADRs per patient was 0.2 (1.46) in cohort A and 0.2 (0.67) in group B, and the rate of ADRs\/year was 0.15 (95% CI: 0.06; 0.34) in cohort A and 0.06 (95% CI: 0.01; 0.38) in cohort B. The majority of patients preferred home-based infusions (cohort A: 93.6%; cohort B: 88.9%), and the main reason was attributed to treatment convenience (cohort A: 93.6%; cohort B: 100%). Despite the underlying conditions, most patients self-evaluated their health as \u201cFair\u201d in cohort A (36.2%) and \u201cGood\u201d in cohort B (44.5%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The use of ERT with \u03b1-glucosidase and alpha-L-iduronidase alfa remains a strong candidate for home therapy, with favorable safety profile, improved treatment ERT compliance, and patient satisfaction. NCT05073783.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04108-1","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T10:15:08Z","timestamp":1763720108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term safety outcomes and patient preferences for home-based intravenous enzyme replacement therapy (ERT) in Pompe disease and Mucopolysaccharidosis Type I (MPS-I): final results of two-year observation"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3995-4827","authenticated-orcid":false,"given":"Antonio","family":"Toscano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olimpia","family":"Musumeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Sacchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Ravaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Siciliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Fiumara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Verrecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Fischetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Crescimanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Taurisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Sechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Cianci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Brighina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalia","family":"Cianflone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Balzarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Parini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"3","key":"4108_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249\u201354. https:\/\/doi.org\/10.1001\/jama.281.3.249.","journal-title":"JAMA"},{"issue":"24","key":"4108_CR2","doi-asserted-by":"publisher","first-page":"476","DOI":"10.21037\/atm.2018.11.39","volume":"6","author":"A Sun","year":"2018","unstructured":"Sun A. Lysosomal storage disease overview. Ann Transl Med. 2018;6(24):476. https:\/\/doi.org\/10.21037\/atm.2018.11.39.","journal-title":"Ann Transl Med"},{"issue":"2","key":"4108_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.pcl.2017.11.011","volume":"65","author":"CM Bellettato","year":"2018","unstructured":"Bellettato CM, Hubert L, Scarpa M, Wangler MF. Inborn errors of metabolism involving complex molecules: lysosomal and peroxisomal storage diseases. Pediatr Clin North Am. 2018;65(2):353\u201373. https:\/\/doi.org\/10.1016\/j.pcl.2017.11.011.","journal-title":"Pediatr Clin North Am"},{"issue":"4","key":"4108_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10897-013-9579-1","volume":"22","author":"R Freedman","year":"2013","unstructured":"Freedman R, Sahhar M, Curnow L, Lee J, Peters H. Receiving enzyme replacement therapy for a lysosomal storage disorder: a preliminary exploration of the experiences of young patients and their families. J Genet Couns. 2013;22(4):517\u201332. https:\/\/doi.org\/10.1007\/s10897-013-9579-1.","journal-title":"J Genet Couns"},{"issue":"4","key":"4108_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","volume":"264","author":"B Schoser","year":"2017","unstructured":"Schoser B, Stewart A, Kanters S, et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase Alfa treatment: a systematic review and meta-analysis. J Neurol. 2017;264(4):621\u201330. https:\/\/doi.org\/10.1007\/s00415-016-8219-8.","journal-title":"J Neurol"},{"issue":"2","key":"4108_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","volume":"90","author":"M Sifuentes","year":"2007","unstructured":"Sifuentes M, Doroshow R, Hoft R, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab. 2007;90(2):171\u201380. https:\/\/doi.org\/10.1016\/j.ymgme.2006.08.007.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"4108_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12883-017-0983-2","volume":"17","author":"B Schoser","year":"2017","unstructured":"Schoser B, Bilder DA, Dimmock D, Gupta D, James ES, Prasad S. The humanistic burden of Pompe disease: are there still unmet needs? A systematic review. BMC Neurol. 2017;17(1):202. https:\/\/doi.org\/10.1186\/s12883-017-0983-2. Published 2017 Nov 22.","journal-title":"BMC Neurol"},{"key":"4108_CR8","doi-asserted-by":"publisher","first-page":"100769","DOI":"10.1016\/j.ymgmr.2021.100769","volume":"28","author":"VM Solano","year":"2021","unstructured":"Solano VM, Mandujano CYC, Avila-Rejon CA, Espin VH, Monta\u00f1o HPQ. Disease burden, management patterns and multidisciplinary clinical approaches for patients with MPS IVA and VI in selected Latin American countries. Mol Genet Metab Rep. 2021;28:100769. https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100769. Published 2021 May 25.","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"4108_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2174\/1872214808666140115111350","volume":"8","author":"S Ortolano","year":"2014","unstructured":"Ortolano S, Vi\u00e9itez I, Navarro C, Spuch C. Treatment of lysosomal storage diseases: recent patents and future strategies. Recent Pat Endocr Metab Immune Drug Discov. 2014;8(1):9\u201325. https:\/\/doi.org\/10.2174\/1872214808666140115111350.","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"issue":"16","key":"4108_CR10","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1002\/ajmg.a.31831","volume":"143A","author":"G W\u0119grzyn","year":"2007","unstructured":"W\u0119grzyn G, Tylki-Szyma\u0144ska A, Liberek A, et al. Rapid deterioration of a patient with mucopolysaccharidosis type I during interruption of enzyme replacement therapy. Am J Med Genet A. 2007;143A(16):1925\u20137. https:\/\/doi.org\/10.1002\/ajmg.a.31831.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"4108_CR11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s10545-006-0237-8","volume":"29","author":"AT Anbu","year":"2006","unstructured":"Anbu AT, Mercer J, Wraith JE. Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I. J Inherit Metab Dis. 2006;29(1):230\u20131. https:\/\/doi.org\/10.1007\/s10545-006-0237-8.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"4108_CR12","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ymgme.2012.08.013","volume":"107","author":"A Jurecka","year":"2012","unstructured":"Jurecka A, \u017buberuber Z, Opoka-Winiarska V, W\u0119grzyn G, Tylki-Szyma\u0144ska A. Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature. Mol Genet Metab. 2012;107(3):508\u201312. https:\/\/doi.org\/10.1016\/j.ymgme.2012.08.013.","journal-title":"Mol Genet Metab"},{"issue":"14","key":"4108_CR13","doi-asserted-by":"publisher","first-page":"892","DOI":"10.12968\/bjon.2010.19.14.49047","volume":"19","author":"R Parini","year":"2010","unstructured":"Parini R, Pozzi K, Di Mauro S, Furlan F, Rigoldi M. Intravenous enzyme replacement therapy: hospital vs home. Br J Nurs. 2010;19(14):892\u20138. https:\/\/doi.org\/10.12968\/bjon.2010.19.14.49047.","journal-title":"Br J Nurs"},{"issue":"6","key":"4108_CR14","doi-asserted-by":"publisher","first-page":"330","DOI":"10.12968\/bjon.2006.15.6.20681","volume":"15","author":"A Milligan","year":"2006","unstructured":"Milligan A, Hughes D, Goodwin S, Richfield L, Mehta A. Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs. 2006;15(6):330\u20133. https:\/\/doi.org\/10.12968\/bjon.2006.15.6.20681.","journal-title":"Br J Nurs"},{"issue":"10","key":"4108_CR15","doi-asserted-by":"publisher","first-page":"653","DOI":"10.12968\/bjon.2008.17.10.29481","volume":"17","author":"A Cousins","year":"2008","unstructured":"Cousins A, Lee P, Rorman D, et al. Home-based infusion therapy for patients with Fabry disease. Br J Nurs. 2008;17(10):653\u20137. https:\/\/doi.org\/10.12968\/bjon.2008.17.10.29481.","journal-title":"Br J Nurs"},{"key":"4108_CR16","doi-asserted-by":"publisher","first-page":"100788","DOI":"10.1016\/j.ymgmr.2021","volume":"28","author":"D Elstein","year":"2021","unstructured":"Elstein D, Giugliani R, Muenzer J, Schenk J, Schwartz IVD, Anagnostopoulou C. Impact of the COVID-19 pandemic on the standard of care for patients with lysosomal storage diseases: A survey of healthcare professionals in the Fabry, Gaucher, and Hunter outcome survey registries. Mol Genet Metab Rep. 2021;28:100788. https:\/\/doi.org\/10.1016\/j.ymgmr.2021.","journal-title":"Mol Genet Metab Rep"},{"issue":"3","key":"4108_CR17","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ymgme.2020.04.002","volume":"130","author":"A Sechi","year":"2020","unstructured":"Sechi A, Macor D, Valent S, et al. Impact of COVID-19 related healthcare crisis on treatments for patients with lysosomal storage disorders, the first Italian experience. Mol Genet Metab. 2020;130(3):170\u20131. https:\/\/doi.org\/10.1016\/j.ymgme.2020.04.002.","journal-title":"Mol Genet Metab"},{"key":"4108_CR18","doi-asserted-by":"publisher","first-page":"100971","DOI":"10.1016\/j.ymgmr.2023.100971","volume":"35","author":"R Heinrich","year":"2023","unstructured":"Heinrich R, Claus F, Schoenfelder T. The patients` perspective on home-based infusion: A longitudinal observational study in the German healthcare setting for patients with lysosomal storage disorders treated with enzyme replacement therapy. Mol Genet Metab Rep. 2023;35:100971. https:\/\/doi.org\/10.1016\/j.ymgmr.2023.100971. Published 2023 Mar 29.","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"4108_CR19","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s13023-023-02919-8","volume":"18","author":"A Toscano","year":"2023","unstructured":"Toscano A, Musumeci O, Sacchini M, et al. Safety outcomes and patients\u2019 preferences for home-based intravenous enzyme replacement therapy (ERT) in Pompe disease and mucopolysaccharidosis type I (MPS-I) disorder: COVID-19 and beyond. Orphanet J Rare Dis. 2023;18(1):338.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"4108_CR20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.33588\/rn.5408.2012088","volume":"54","author":"MA Barba-Romero","year":"2012","unstructured":"Barba-Romero MA, Barrot E, Bautista-Lorite J, et al. Clinical guidelines for late-onset Pompe disease. Rev Neurol. 2012;54(8):497\u2013507.","journal-title":"Rev Neurol"},{"issue":"10","key":"4108_CR21","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1111\/imj.15473","volume":"51","author":"U Ramaswami","year":"2021","unstructured":"Ramaswami U, D\u2019Amore S, Finnegan N, Hughes D, Kazemi M, Lysosomal Disorders Team, Royal Free London NHS Foundation Trust. Impact of SARS-CoV-2 (COVID-19) pandemic on patients with Lysosomal storage disorders and restoration of services: experience from a specialist centre. Intern Med J. 2021;51(10):1580\u201393. https:\/\/doi.org\/10.1111\/imj.15473.","journal-title":"Intern Med J"},{"key":"4108_CR22","doi-asserted-by":"publisher","unstructured":"Fiumara A, Lanzafame G, Arena A, et al. COVID-19 Pandemic outbreak and its psychological impact on patients with rare lysosomal diseases. J Clin Med. 2020;9(9):2716. Published 2020 Aug 22. https:\/\/doi.org\/10.3390\/jcm9092716","DOI":"10.3390\/jcm9092716"},{"key":"4108_CR23","unstructured":"European Medicines Agency, Aldurazyme, INN-laronidase - Summary of Product Characteristics [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aldurazyme-epar-product-information_en.pdf"},{"key":"4108_CR24","unstructured":"Agency EM. Myozyme. INN-alglucosidase alfa \u2013 Summary of Product Characteristics [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/myozyme-epar-product-information_en.pdf"},{"issue":"5","key":"4108_CR25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s40259-023-00609-2","volume":"37","author":"IAM Ditters","year":"2023","unstructured":"Ditters IAM, van Kooten HA, van der Beek NAME, et al. Home-Based infusion of alglucosidase Alfa can safely be implemented in adults with Late-Onset Pompe disease: lessons learned from 18,380 infusions. BioDrugs. 2023;37(5):685\u201398. https:\/\/doi.org\/10.1007\/s40259-023-00609-2.","journal-title":"BioDrugs"},{"issue":"3","key":"4108_CR26","doi-asserted-by":"publisher","first-page":"107611","DOI":"10.1016\/j.ymgme.2023.107611","volume":"139","author":"LER Lessard","year":"2023","unstructured":"Lessard LER, Tard C, Salort-Campana E, et al. Hypersensitivity infusion-associated reactions induced by enzyme replacement therapy in a cohort of patients with late-onset Pompe disease: an experience from the French Pompe registry. Mol Genet Metab. 2023;139(3):107611. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107611.","journal-title":"Mol Genet Metab"},{"issue":"22","key":"4108_CR27","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.12968\/bjon.2007.16.22.27768","volume":"16","author":"DA Hughes","year":"2007","unstructured":"Hughes DA, Mlilligan A, Mehta A. Home therapy for lysosomal storage disorders. Br J Nurs. 2007;16(22):1384\u20139. https:\/\/doi.org\/10.12968\/bjon.2007.16.22.27768.","journal-title":"Br J Nurs"},{"key":"4108_CR28","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3390\/jcm14030842","volume":"14","author":"B Kie\u00b4c-Wilk","year":"2025","unstructured":"Kie\u00b4c-Wilk B, Guijt P, Dan M, et al. Home enzyme replacement therapy in gaucher disease: A review. J Clin Med. 2025;14:842.","journal-title":"J Clin Med"},{"key":"4108_CR29","first-page":"1002","volume":"24","author":"L Nalysnyk","year":"2018","unstructured":"Nalysnyk L, Sugarman R, Cele C, et al. A. Budget impact analysis of eliglustat for the treatment of gaucher disease type 1 in the united States. J Manag Care Spec Pharm. 2018;24:1002\u20138.","journal-title":"J Manag Care Spec Pharm"},{"key":"4108_CR30","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s13023-024-03492-4","volume":"19","author":"R Heinrich","year":"2024","unstructured":"Heinrich R, Claus F, Schoenfelder T. Health care costs of home care enzyme replacement therapy for patients with lysosomal storage diseases in Germany. Orphanet J Rare Dis. 2024;19:462.","journal-title":"Orphanet J Rare Dis"},{"key":"4108_CR31","unstructured":"Hughes DA, Evans S, Milligan A, et al. A multidisciplinary approach to the care of patients with Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. [Internet] Oxford: Oxford Pharma Genesis; 2006. Available from http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK11587\/"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04108-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04108-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04108-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:16:36Z","timestamp":1781615796000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-04108-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4108"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04108-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"7 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures followed were in accordance with the ethical standards of the committee responsible for human experimentation (institutional and national). This study was conducted in accordance with the Declaration of Helsinki of 1975, as revised in 2000, and Good Pharmacoepidemiology Practices (GPPs). The study protocols and questionnaire were approved by the Ethical Review Board of the local committee at all participating sites. Written informed consent was obtained from all individual participants included in the study. Eligibility of the participants was at the discretion of the physician and based on standard treatment options as determined by the Italian regulations (including AIFA authorization 341\/2020 for Pompe disease patients and MPS-I patients). Dosage and dosage regimen were in accordance with the Summary of Product Characteristics (SmPC).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This article does not contain any studies with animal subjects performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal rights"}},{"value":"MS, EV, GC, RT, SG, RF, and VC have no conflict of interest to declare. AF received support from Sanofi and PIAM for meetings\/travelling and was part of a Data Safety Monitoring Board or Advisory Board for Sanofi. LM received grants or contracts from Biogen, Alexion\/Astrazeneca for fellowship; payment or honoraria for lectures, presentations, manuscript writing or educational events from Biogen, Alexion, Argenx, UCB, Johnson and Johnson, Lupin Therapeutics, Roche, Sanofi, and Amicus therapeutics; and support for attending meetings and\/or travel from Biogen, Alexion, Argenx, UCB, Roche, and Sanofi. OM received support for attending meetings and\/or travel from Sanofi; and was part of a Data Safety Monitoring Board or Advisory Board for Sanofi and Amicus therapeutics. SR was part of a Data Safety Monitoring Board or Advisory Board for Sanofi and Amicus. AT received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, as well as support for attending meetings and\/or travel, from Sanofi, Amicus, and Astellas. RB received consulting fees from Glycomine; support for attending meetings and\/or travel from Sanofi; and leadership or fiduciary role in other board, society, committee or advocacy group (unpaid) for SIMMESN, AIMPS, and CDG-Italia. AS received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Sanofi Genzyme, Amicus, Takeda-Shire; Support for attending meetings and\/or travel from Sanofi Genzyme, Amicus, Takeda-Shire. FB received support for attending meetings and\/or travel from Sanofi, Alnylam, and Roche. GS received grants or contracts from Sanofi, Roche, Italfarmaco; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Biogen, Johnson and Johnson, Lupin Therapeutics, Roche, Sanofi, Amicus therapeutics, Zambon, Takeda, CSL; support for attending meetings and\/or travel from Biogen, Alexion, Argenx, Roche, Sanofi. AC received support from Sanofi for attending meetings and\/or travel. MB received payment or honoraria from Sanofi for lectures, presentations, speakers bureaus, manuscript writing or educational events; Support for attending meetings and\/or travel from Sanofi and Takeda Shire. RP received support for attending meetings from Sanofi and Orchard Therapeutics.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"639"}}